Although the mTOR inhibitor, Everolimus, as a single agent did not significantly improve the overall survival (OS) of patients with AGC in whom progression occurred after one or two lines of previous systemic chemotherapy [10], inhibition of the mTOR pathway could be a strategy to improve Tmab efficacy in patients with HER2+ GC. This evidence concerns the gene ERBB2 and gastric cancer.